Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v4-EN
Language French English
Date Updated 2020-03-30 2020-03-30
Drug Identification Number 02444038 02444038
Brand name MIFEGYMISO MIFEGYMISO
Common or Proper name Mifepristone/Misoprostol Mifepristone/Misoprostol
Company Name LINEPHARMA INTERNATIONAL LIMITED LINEPHARMA INTERNATIONAL LIMITED
Ingredients MISOPROSTOL MIFEPRISTONE MISOPROSTOL MIFEPRISTONE
Strength(s) 200MCG 200MG 200MCG 200MG
Dosage form(s) KIT TABLET KIT TABLET
Route of administration BUCCAL ORAL BUCCAL ORAL
Packaging size Combipack (1 box of tablet of mifepristone 200mg tablet + 1 box of 4 tablets of 200ug misoprostol Combipack (1 box of tablet of mifepristone 200mg tablet + 1 box of 4 tablets of 200ug misoprostol
ATC code G03XB G03XB
ATC description OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date 2020-02-06 2020-02-06
Actual start date 2020-02-06 2020-02-06
Estimated end date 2020-02-14 2020-02-14
Actual end date 2020-03-27 2020-03-27
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Linepharma International Limited considers that this shortage situation has a very low impact on public health since product is due to be made available in a week Linepharma International Limited considers that this shortage situation has a very low impact on public health since product is due to be made available in a week
Health Canada comments